• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Abeona Therapeutics Inc.

    6/26/26 4:33:59 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABEO alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on June 26, 2026.

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Abeona Therapeutics Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   83-0221517
    (State or other jurisdiction
    of incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    6555 Carnegie Ave, 4th Floor, Cleveland, OH 44103

     

    (Address of Principal Executive Offices)

    (Zip Code)

     

    Second Amended and Restated Abeona Therapeutics Inc.

    2023 Equity Incentive Plan

     

    (Full title of the plan)

     

    Joseph Vazzano

    Chief Financial Officer

    Abeona Therapeutics Inc.

    6555 Carnegie Ave, 4th Floor

    Cleveland, OH 44103

    (646) 813-4701

     

    (Name, address, and telephone number, including area code, of agent for service)

     

    Copies of Correspondence to:

     

    Brian V. Soares
    Carlton Fields, P.A.

    4221 W Boy Scout Blvd., Suite 1000
    Tampa, FL 33607

    (813) 223-7000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    On March 16, 2026, the Board of Directors of Abeona Therapeutics Inc. (the “Registrant”) approved an amendment to the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan (as amended and restated, the “Plan”), which includes an increase in the number of shares of common stock of the Registrant, par value $0.01 per share (the “Common Stock”), available for issuance under the Plan. On June 12, 2026, stockholders voted to approve the Plan. This Registration Statement on Form S-8 is being filed to register 3,100,000 additional shares of Common Stock that may become available for issuance under the Plan pursuant to its terms.

     

    The Registrant previously filed the following registration statements on Form S-8: Registration No. 333-272103 on May 19, 2023, Registration No. 333-279428 on May 15, 2024, and Registration No. 333-284151 on January 6, 2025 (collectively, the “Prior Registration Statements”), pursuant to which the Registrant previously registered the offer and sale of an aggregate of 8,400,000 shares of Common Stock. As of the date of this Registration Statement, of the 8,400,000 shares of Common Stock that have been made available for issuance under the Plan: (a) 6,950,226 shares of Common Stock have been issued pursuant to awards issued thereunder (“Issued Shares”), (b) 4,744,531 shares of Common Stock are subject to outstanding, but unexercised, awards, and (c) 1,449,774 shares of Common Stock are available for future awards. The additional shares of Common Stock being registered by this Registration Statement are of the same class as those securities registered on the Prior Registration Statements and represent an increase in the total shares available for issuance under the Plan by 3,100,000 shares to 11,500,000 shares. Pursuant to General Instruction E to Form S-8, this Registration Statement incorporates by reference the contents of the Prior Registration Statements, including all exhibits filed therewith or incorporated therein by reference, to the extent not modified or superseded hereby or by any subsequently filed document that is incorporated by reference herein or therein.

     

    -2-

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:

     

      (i) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (filed with the Commission on March 17, 2026);
         
      (ii) The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 (filed with the Commission on May 13, 2026);
         
      (iii) The Registrant’s Current Reports on Form 8-K filed with the Commission on March 9, 2026, March 20, 2026, April 7, 2026, June 4, 2026, June 11, 2026, and June 12, 2026; and
         
      (iv) The description of our common stock, par value $0.01 per share contained in our Registration Statement on Form 8-A, dated and filed with the SEC on November 4, 2014, as updated by Exhibit 4.4 to our Form 10-K for the fiscal year ended December 31, 2019, and including any amendments or reports filed with the SEC for the purpose of updating such description.

     

    To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, was furnished to, rather than filed with, the Commission, such information or exhibit is specifically not incorporated by reference.

     

    All reports and other documents that the Company subsequently files with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that the Company has sold all of the securities offered under this Registration Statement or deregisters the distribution of all such securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date that the Company files such report or document.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    The validity of the securities registered hereby is being passed upon for us by Carlton Fields, P.A. One or more partners or other employees of Carlton Fields, P.A. may beneficially own shares of the Registrant’s Common Stock.

     

    Item 6. Indemnification of Directors and Officers.

     

    Not applicable.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    -3-

     

     

    Item 8. Exhibits.

     

    A list of exhibits filed herewith is contained in the Exhibit Index below, which is incorporated herein by reference.

     

    EXHIBIT INDEX

     

            Incorporated by Reference    
    Exhibit No.   Description   Form   File No.   Exhibit   Filing Date   Filed Herewith
    4.1   Restated Certificate of Incorporation of Abeona Therapeutics Inc.   10-Q   001-15771   3.1   May 10, 2019    
    4.2   Certificate of Amendment to Restated Certificate of Incorporation of Abeona Therapeutics Inc.   8-K   001-15771   3.1   June 30, 2022    
    4.3   Amended and Restated Bylaws of Abeona Therapeutics Inc.   10-K   001-15771   3.3   March 17, 2026    
    5.1   Opinion of Carlton Fields, P.A.                   X
    23.1   Consent of Deloitte & Touche LLP                   X
    23.2   Consent of Carlton Fields, P.A. (included in Exhibit 5.1 hereto)                   X
    24.1   Powers of Attorney (included in the signature page of this Registration Statement)                   X
    99.1 Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan   DEF 14A   001-15771   Appendix A    April 27, 2026    
    107.1   Filing Fee Table                   X

     

    -4-

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Morristown, in the state of New Jersey, on the 26th day of June, 2026.

     

      ABEONA THERAPEUTICS INC.
         
      By: /s/ Joseph Vazzano
        Joseph Vazzano
        Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

     

    -5-

     

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby appoints Vishwas Seshadri and Joseph Vazzano and each of them, severally, as his or her true and lawful attorney or attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including all pre-effective and post-effective amendments and registration statements filed pursuant to Rule 462 under the Securities Act of 1933, as amended), and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and dates indicated.

     

    Signature   Title   Date
             
    /s/ Vishwas Seshadri   President, Chief Executive Officer and Director (Principal Executive Officer)   June 26, 2026
    Vishwas Seshadri        
             
    /s/ Joseph Vazzano   Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)   June 26, 2026
    Joseph Vazzano        
             
    /s/ Leila Alland   Director   June 26, 2026
    Leila Alland        
             
    /s/ Mark Alvino   Director   June 26, 2026
    Mark Alvino        
             
    /s/ Faith Charles   Director   June 26, 2026
    Faith Charles        
             
    /s/ Eric Crombez   Director   June 26, 2026
    Eric Crombez        
             
    /s/ Keith Goldan   Director   June 26, 2026
    Keith Goldan        
             
    /s/ Donald Wuchterl   Director   June 26, 2026
    Donald Wuchterl        
             
    /s/ Bernhardt Zeiher   Director   June 26, 2026
    Bernhardt Zeiher        

     

    -6-

     

     

    Get the next $ABEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABEO

    DatePrice TargetRatingAnalyst
    6/2/2025$19.00Outperform
    Oppenheimer
    3/5/2025$16.00Outperform
    Oppenheimer
    7/3/2024$15.00Buy
    H.C. Wainwright
    5/30/2024$21.00Buy
    Stifel
    11/30/2021$5.00 → $1.00Outperform → Market Perform
    SVB Leerink
    11/29/2021$5.00 → $4.00Buy
    HC Wainwright & Co.
    7/19/2021$8.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ABEO
    SEC Filings

    View All

    SEC Form S-8 filed by Abeona Therapeutics Inc.

    S-8 - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

    6/26/26 4:33:59 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

    6/12/26 4:30:25 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

    6/12/26 7:30:20 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Abeona Therapeutics with a new price target

    Oppenheimer resumed coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $19.00

    6/2/25 8:44:24 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Abeona Therapeutics with a new price target

    Oppenheimer initiated coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $16.00

    3/5/25 7:50:58 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Abeona Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Abeona Therapeutics with a rating of Buy and set a new price target of $15.00

    7/3/24 7:23:46 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Vasanthavada Madhav disposed of $1,259 worth of shares (222 units at $5.67), decreasing direct ownership by 0.07% to 303,229 units (SEC Form 4) (withholding tax)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    6/17/26 4:30:22 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Silverstein Christine Berni sold $103,695 worth of shares (18,160 units at $5.71), decreasing direct ownership by 13% to 119,562 units (SEC Form 4) to satisfy tax liability

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    6/15/26 7:48:40 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Vasanthavada Madhav sold $51,549 worth of shares (9,620 units at $5.36), decreasing direct ownership by 3% to 303,451 units (SEC Form 4) to satisfy withholding obligation

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    6/9/26 8:32:53 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Alland Leila bought $51,799 worth of shares (11,000 units at $4.71), increasing direct ownership by 15% to 82,857 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    5/20/24 8:30:14 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seshadri Vishwas bought $32,000 worth of shares (10,000 units at $3.20), increasing direct ownership by 2% to 538,260 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/29/24 8:30:16 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Charles Faith L. bought $24,764 worth of shares (7,550 units at $3.28), increasing direct ownership by 11% to 78,323 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/29/24 8:30:14 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On May 31, 2026, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 13,800 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the s

    6/1/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

    CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026: 2026 Jefferies Global Healthcare Conference: Fireside chat at 3:10 PM ET on Thursday, June 4, 2026 and investor meetings.Goldman Sachs 47th Annual Global Healthcare Conference 2026: Investor meetings on Monday, June 8, 2026. A live webcast of the fireside chat can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events, where a replay of the event will also be available for a limited time. About Abeona Therapeutics Abeona

    5/26/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

    - Three patients treated with ZEVASKYN® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast -  - In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized - - $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 - - Webcast today at 8:30am ET - CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN. Steady increase in ZEVASKYN adoption with three patients completing treatment in the first

    5/13/26 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Leadership Updates

    Live Leadership Updates

    View All

    Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

    CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona's continued focus on strengthening its leadership team to advance both strategic and financial objectives. "On behalf of the Board, we are delighted to welcome Keith to Abeona," sa

    4/7/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

    CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy and business development functions, as well as drive operating efficiency for the Company. "Mohamad brings a wealth of experience in strategic planning and business development," said Vish Seshadri, Chief Executive Officer of Abeona. "We look forward to leveraging his extensive network and proven expertise to optimize our operations and guide Abeona toward value-creating partnerships." Mr. Tabrizi transitions to Abeon

    12/15/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

    CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately. "We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Officer of Abeona. "James has a proven track record of leading novel gene therapy programs for inherited retinal diseases. His addition to our team will be invaluable as we advance our pipeline and deliver transformative treatments to patients."

    10/20/25 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    10/8/24 4:29:58 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abeona Therapeutics Inc. (Amendment)

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    6/3/24 4:30:14 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Financials

    Live finance-specific insights

    View All

    Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

    - Three patients treated with ZEVASKYN® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast -  - In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized - - $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 - - Webcast today at 8:30am ET - CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN. Steady increase in ZEVASKYN adoption with three patients completing treatment in the first

    5/13/26 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Date of First Quarter Financial Results

    CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial results for the first quarter of 2026 and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 305519 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be avai

    5/4/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

    - First ZEVASKYN® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 - CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the full year of 2025 and recent operational progress. "2026 is about building a steady cadence of biopsies and treatments," said Vish Seshadri, Chief Executive Officer of Abeona. "We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us

    3/17/26 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care